- Conditions
- Argininosuccinic Aciduria, Amino Acid Metabolism, Inborn Errors, Urea Cycle Disorders
- Interventions
- Sodium Phenylbutyrate, Arginine
- Drug
- Lead sponsor
- Brendan Lee
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 52
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Urea Cycle Disorders
- Interventions
- HPN-100, Buphenyl (NaPBA)
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 21
- States / cities
- Long Beach, California • Los Angeles, California • Stanford, California + 18 more
- Conditions
- Inclusion Body Myositis, Sporadic Inclusion Body Myositis
- Interventions
- Phenylbutyrate Oral Tablet
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- chemotherapy, oral sodium phenylbutyrate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Leukemia
- Interventions
- sargramostim, dexamethasone, oral sodium phenylbutyrate
- Biological · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 4
- States / cities
- Bethesda, Maryland • New York, New York • Pittsburgh, Pennsylvania
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases, Spinal Cord Diseases, TDP-43 Proteinopathies, Nervous System Diseases, Central Nervous System Diseases
- Interventions
- AMX0035, Placebo
- Drug · Other
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Orange, California • San Francisco, California + 21 more
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Sodium phenylbutyrate
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 1 Day to 6 Months
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cystic Fibrosis
- Interventions
- Ravicti low dose, Placebo
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- AMX0035
- Drug
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- San Francisco, California • Boston, Massachusetts • Worcester, Massachusetts + 2 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- AMX0035
- Drug
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 14 more
- Conditions
- Urea Cycle Disorders
- Interventions
- HPN-100
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 12 more
- Conditions
- Cirrhosis, Hepatic Encephalopathy
- Interventions
- HPN-100, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 28
- States / cities
- Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 21 more
- Conditions
- Urea Cycle Disorders
- Interventions
- HPN-100, NaPBA
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • New York, New York + 4 more
- Conditions
- Urea Cycle Disorders
- Interventions
- HPN-100, BUPHENYL®
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Houston, Texas
- Conditions
- Insulin Resistance, Diabetes, Obesity
- Interventions
- tauroursodeoxycholic acid, placebo, sodium phenylbutyrate
- Drug · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Medium-chain Acyl-CoA Dehydrogenase Deficiency
- Interventions
- Sodium phenylbutyrate
- Drug
- Lead sponsor
- Jerry Vockley, MD, PhD
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency
- Interventions
- Ravicti
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Urea Cycle Disorder
- Interventions
- RAVICTI
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 1 Day to 2 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 13 more
- Conditions
- Alzheimer Disease
- Interventions
- AMX0035, Placebo
- Drug
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Industry
- Eligibility
- 55 Years to 89 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Orlando, Florida • Palmetto Bay, Florida + 7 more
- Conditions
- Wolfram Syndrome
- Interventions
- AMX0035
- Drug
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Industry
- Eligibility
- 17 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Urea Cycle Disorders
- Interventions
- HPN-100
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 29 Days to 6 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Portland, Maine + 5 more
- Conditions
- ACHROMATOPSIA 7, Achromatopsia
- Interventions
- PBA
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cystic Fibrosis
- Interventions
- Sodium 4-Phenylbutyrate, Genistein (Unconjugated Isoflavones 100), Placebo
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Brain Neoplasms, Neuroblastoma
- Interventions
- phenylbutyrate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland